Search clinical trials for: Trypsin Inhibitors

Total 64195 results

Dartmouth-Hitchcock Medical Center

Terminated

Phase I Study of Aprotinin in Advanced Breast Cancer

Metastatic Breast Cancer

United States
Aviron LLC

Unknown

An Open Non-comparative Study of the Efficacy and Safety of Aprotinin in Patients Hospitalized With COVID-19

COVID-19

Russian Federation
University of Michigan Rogel Cancer Center
CSL Behring; The Leukemia and Lymphoma Society

Completed

A Pilot Study of Alpha-1-Antitrypsin (AAT) in Steroid Refractory Acute Graft vs Host Disease

Graft vs Host Disease

United States
Rabin Medical Center

Unknown

Safety and Efficacy of Inhaled Alpha-1 Antitrypsin in Preventing Bronchiolitis Obliterable Syndrome in Lung Transplant Recipients

Lung Transplantation | Bronchiolitis Obliterable Syndrome
Yale University
Ono Pharmaceutical Co. Ltd

Withdrawn

The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular Complications

COVID-19 | Coagulopathy | Cardiovascular Complication
Université de Sherbrooke

Terminated

Alpha1 Antitrypsin Aerosol Therapy in Cystic Fibrosis

Cystic Fibrosis

Canada
Institute for Human Genetics and Biochemistry
Grifols Biologicals, LLC; AIDS Community Research Initiative of America

Terminated

Safety and Efficacy of (α1Proteinase Inhibitor, α1PI) in HIV Disease

HIV Disease

United States
Kamada, Ltd.

Completed

Phase II Study of the Safety and Efficacy of Inhaled Alpha-1 Antitrypsin (AAT ) in Cystic Fibrosis Patients

Cystic Fibrosis

Israel
Inhibrx, Inc.

Recruiting

Study of INBRX-101 Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema (ELEVAATE)

Emphysema | Alpha 1-Antitrypsin Deficiency

United States, Australia, United Kingdom, New Zealand
Ono Pharmaceutical Co. Ltd

Completed

Multiple-dose Study of FOY-305 in Japanese Healthy Adult Male Subjects

Healthy Volunteers

Japan
Octapharma

Withdrawn

Study Comparing Weekly Intravenous Administration of OctaAlpha1 With a Marketed Preparation Glassia® in Subjects With Alpha-1-antitrypsin Deficiency

Alpha 1-Antitrypsin Deficiency
Baxalta now part of Shire
Baxter Healthcare, Ltd. (New Zealand), Baxter Healthcare Pty. Ltd. (Australia)

Completed

Pharmacokinetic Study of ARALAST (Human Alpha1- PI)

Alpha 1-Antitrypsin Deficiency

Australia, New Zealand
CSL Behring

Recruiting

The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant (MODULAATE)

Acute-graft-versus-host Disease

United States, Korea, Republic of, Spain, Australia, Germany, Italy, Turkey, Japan
Peking University Third Hospital
Chinese PLA General Hospital; The First Affiliated Hospital of Zhengzhou University and other collaborators

Completed

Prevention of Ulinastatin on Acute Respiratory Distress Syndrome (ARDS)

Critical Illness | Acute Respiratory Distress Syndrome

China
Huazhong University of Science and Technology

Not yet recruiting

Effect of Ulinastatin on the Action of NDMRs (Rocuronium / Cisatracurium)

Nondepolarising Muscle Relaxants

China
Medical University of South Carolina
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Alpha-1 Antitrypsin (AAT) Enhances Islet Autograft Survival in Patients With Chronic Pancreatitis

Chronic Pancreatitis

United States
Qin Zhang

Recruiting

Ulinastatin Improves and Prevents Cardiac Dysfunction Induced by Cardiopulmonary Bypass

Pharmacological Action

China
Impatients N.V. trading as myTomorrows
Kamada, Ltd.

No longer available

Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After Hematopoietic Stem Cell Transplantation (HSCT)

Alpha 1-Antitrypsin Deficiency | Graft Vs Host Disease | Graft-versus-host-disease | Acute-graft-versus-host Disease | Steroid Refractory Acute Graft Versus Host Disease | Alpha-1 Proteinase Inhibitor | Alpha-1 Protease Inhibitor Deficiency | Acute Graft-Versus-Host Reaction Following Bone Marrow...
National Institute of Allergy and Infectious Diseases...
Juvenile Diabetes Research Foundation; Immune Tolerance Network (ITN)

Withdrawn

A Research Trial of Aralast NP in New Onset Diabetes (RETAIN) - Part II (RETAIN)

Diabetes Mellitus, Type 1

United States
Bayer

No longer available

Aprotinin US Special Access Protocol

Postoperative Hemorrhage

United States
Soroka University Medical Center

Unknown

Effect of Intraoperative Aprotinin Administration on Post Cardiac Surgery Optic Nerve and Retinal Thickness.

Cardiac Surgery

Israel
Ajou University School of Medicine

Unknown

The Effect of Ulistin on Acute Renal Injury in Patients Undergoing OPCAB (Off Pump Coronary Artery Bypass): a Propensity Score Matched Study

Acute Kidney Injury
Grifols Therapeutics LLC

Recruiting

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency

Alpha1-Antitrypsin Deficiency

United States
Takeda

Withdrawn

A Study of RYMPHYSIA for Alpha1-Proteinase Inhibitor (A1PI) Therapy in Adults With A1PI Deficiency and Chronic Obstructive Pulmonary Disease (COPD)-Emphysema

Chronic Obstructive Pulmonary Disease (COPD) | Alpha1-Antitrypsin Deficiency
Kamada, Ltd.
Syneos Health

Recruiting

Evaluate Efficacy and Safety of "Kamada-AAT for Inhalation" in Patients With AATD (InnovAATe)

Alpha 1-Antitrypsin Deficiency

United Kingdom, Sweden, Ireland, Netherlands, Belgium, Finland
CSL Behring
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Active, not recruiting

Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone (BMT CTN 1705)

Graft Versus Host Disease (GVHD)

United States
Kamada, Ltd.

Completed

Phase II Study to Evaluate the Efficacy and Safety of Glassia® in Type-1 Diabetes

New Onset Type-1 Diabetes

Israel
Oslo University Hospital

Completed

Different Regimen of Aprotinine(Trasylol) Administration in Patients Receiving Antiplatelet Therapy With Clopidogrel (Plavix)

Coronary Artery Disease
Nanjing Medical University
Beijing Anzhen Hospital

Completed

Additive Anti-inflammatory Action for Aortopathy & Arteriopathy (Ulinastatin) II

Acute Aortic Syndrome | Type A Aortic Dissection

China
Alan Bryce

Unknown

Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19 (RECOVER)

Severe Acute Respiratory Syndrome

United States
Konkuk University Medical Center

Completed

Ulinastatin Improves Postoperative Oxygenation After Cardiopulmonary Bypass

Cardiac Surgery | Cardiopulmonary Bypass

Korea, Republic of
Cancer Research UK
Latus Therapeutics

Terminated

A Trial Looking at the Use of Camostat in People Who Have Tested Positive for Coronavirus (COVID-19) (SPIKE-1) (SPIKE-1)

COVID-19 Infection

United Kingdom
Bayer

Terminated

Efficacy and Safety of Aprotinin on Transfusion Requirements in Patients Undergoing Radical or Total Cystectomy

Blood Loss, Surgical | Postoperative Hemorrhage

Belgium, United States, Sweden, Germany, Netherlands, United Kingdom, France
Bayer

Terminated

Study to Investigate the Effect of Aprotinin of Transfusion Requirements in Patients Undergoing Surgical Procedures for Lung or Esophageal Cancer

Blood Loss, Surgical

United States, Australia, Austria, Belgium, Canada, Denmark, France, Germany, Spain, United Kingdom
Grifols Therapeutics LLC

Completed

Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency (SPARK)

Emphysema | Alpha 1-antitrypsin Deficiency (AATD)

United States
Universität des Saarlandes

Completed

Alpha-1-Antitrypsin-Deficiency in COVID-19 (CORSAAR-AAT)

Covid19

Germany
University of Rostock

Unknown

AKI Cardiosurgery Diagnostic Study (AKI-CDS) (AKI-CDS)

Acute Kidney Injury | Renal Replacement Therapy

Germany
Chinese PLA General Hospital
Changhai Hospital; Southwest Hospital, China; General Hospital of Beijing PLA...

Unknown

Ulinastatin in Inhalation Lung Injury

Inhalation Injury

China
Grifols Therapeutics LLC

Enrolling by invitation

Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency (SPARTA-OLE)

Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency

United States, New Zealand, Denmark, Australia, Finland, Estonia, Canada, Poland, Russian Federation, Sweden, France
Bayer

Completed

Effect of Aprotinin on Transfusion Requirements and Blood Loss in Patients Undergoing Elective Primary Total Hip Replacement

Blood Loss, Surgical

United States, Canada, Puerto Rico
Konkuk University Medical Center

Completed

Ulinastatin's Anti-inflammatory Reaction in Cardiac Surgery (ulistin)

Cardiovascular Disease

Korea, Republic of
Stanford University

Completed

Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients (COPS-2003)

Covid19

United States
Sagent Pharmaceuticals Inc.

Completed

Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT)

COVID-19

United States
Yonsei University

Completed

Effects of Ulinastatin on Coagulation in High Risk Patients Undergoing Off Pump Coronary Artery Bypass Graft Surgery

Coronary Artery Occlusive Disease

Korea, Republic of
Grifols Therapeutics LLC
Grifols Japan K.K.

Completed

Safety and Pharmacokinetics of Alpha-1 MP (Alpha1-proteinase Inhibitor (Human), Modified Process) in Participants With Alpha1-Antitrypsin Deficiency

Alpha1-Antitrypsin Deficiency

Japan
Bayer

Terminated

Effect of Aprotinin on Transfusion Requirements in Patients Undergoing Elective Spinal Fusion Surgery

Blood Loss, Surgical | Postoperative Hemorrhage

Spain, Germany, Canada
Grifols Therapeutics LLC

Completed

A Study to Assess Safety and PK of Liquid Alpha₁-Proteinase Inhibitor (Human) in Treating Alpha₁-Antitrypsin Deficiency

Alpha₁-Antitrypsin Deficiency

United States
University of Colorado, Denver
Omni Bio Pharmaceutical, Inc.

Completed

The Effects of Alpha-1 Antitrypsin (AAT) on the Progression of Type 1 Diabetes

Diabetes | Type 1 Diabetes

United States
Grifols Therapeutics LLC

Completed

The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency (STAMP)

Alpha 1-Antitrypsin Deficiency

United States, United Kingdom
Grifols Therapeutics LLC
Grifols Japan K.K.

Completed

Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficiency (GTI1401-OLE)

Alpha1-Antitrypsin Deficiency

Japan

Search clinical trials for: Trypsin Inhibitors

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sweden

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations